Medexus Pharma (MDP.T) doesn’t have long to go before the release of its next quarterly financials and news could be good. Investors have previously missed the opportunity behind Medexus as it brings already internationally approved specialty drugs to the US and Canadian markets.

Medexus is extremely low-risk compared to drug developers who’s success is hinged on a string of expensive clinical trials leading to FDA approval which may or may not come.

The company has a strong revenue generating portfolio which has grown to match Medexus’ market cap. This unheard of low P/E ratio provides an incredible investment growth opportunity as is, not to mention that Medexus is also in the midst of bringing another drug to North American markets that could add another $100 million to its revenues.

Equity Guru founder, Chris Parry, digs into Medexus, its upcoming challenges and catalysts and why investors should be giving this Canadian specialty pharma venture a serious look.

Enjoy!